The short version
Only one company currently supplies this market — there is no backup if it stumbles.
The numbers behind every sentence are on this page below — and the Watch button emails you when any of them move.
Niktimvo
axatilimab-csfr · AXATILIMAB 9 mg/.18mL · Injection · Intravenous · Incyte Corporation
NDC 50881-0034-12 · 1 VIAL, SINGLE-USE in 1 CARTON / .18 mL in 1 VIAL, SINGLE-USE · BLA · View full market →
Medicare Part D
No Medicare Part D plan in CMS's quarterly files lists this product. That usually means it is discontinued, a repackager's listing, or a product no plan has added to its formulary.
How Part D pricing works →NADAC price per unit
No NADAC pricing on file for this NDC — NADAC covers drugs dispensed by retail community pharmacies.
Estimated fill cost
WAC per package, as filed
$4,797.00
Reported to Texas DSHS · 2026 annual filing · Incyte Corporation
Manufacturer list price as filed — not what pharmacies actually pay after discounts.
Medicare Part B (ASP)
Payment limit per 0.1 MG
$56.461
HCPCS J9038 · Jul 1, 2026 quarter · typically ASP + 6%
Medicaid spend (2025)
$1.1M
163 prescriptions paid by Medicaid nationally · all Medicaid spend →
Supply fragility
Not scored — fragility is computed for NADAC-priced NDCs.
Is this a "specialty" drug?
There's no legal definition — it meets 2 of 6 public criteria. Why that matters →
- Part D specialty tier
- Costs ≥ $950/fill
- Biologic (BLA)
- Injectable / infused
- Orphan-drug exclusivity
- REMS program
Regulatory
- Application
- BLA761411
- TE code
- —
- Approval date
- —
- Patents / exclusivity
- None on file
Shortage history
No FDA shortage reports for this drug or its presentations.
Recalls (this NDC)
No enforcement reports list this package NDC.
Manufacturers of axatilimab-csfr (Injection)
| Labeler | Strength | First seen | Last seen |
|---|---|---|---|
| Incyte Corporation | AXATILIMAB 22 mg/.44mL | Jul 15, 2026 | Sep 2, 2026 |
| Incyte Corporation | AXATILIMAB 22 mg/2.2mL | Jul 15, 2026 | Sep 2, 2026 |
| Incyte Corporation | AXATILIMAB 50 mg/mL | Jul 15, 2026 | Sep 2, 2026 |
| Incyte Corporation | AXATILIMAB 9 mg/.18mL | Jul 15, 2026 | Sep 2, 2026 |
| Incyte Corporation | AXATILIMAB 9 mg/.9mL | Jul 15, 2026 | Sep 2, 2026 |
Roster from daily NDC Directory diffs — first/last seen dates start July 2026.
Cite this page
DrugDashboards, "Niktimvo — NDC 50881-0034-12," retrieved September 3, 2026, https://drugdashboards.com/drug/50881003412.
Free to cite with attribution — see how the data is put together.